相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
Stefanie Gilli et al.
ANNALS OF HEMATOLOGY (2017)
Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis
Hugo J. A. Adams et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network
Camille Laurent et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity
S. Garciaz et al.
BONE MARROW TRANSPLANTATION (2016)
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT
L. Sellner et al.
BONE MARROW TRANSPLANTATION (2016)
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen
Maurizio Musso et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning
Alessandro Isidori et al.
LEUKEMIA & LYMPHOMA (2016)
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Navneet S. Majhail et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
Craig S. Sauter et al.
BLOOD (2015)
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
A. Sureda et al.
BONE MARROW TRANSPLANTATION (2015)
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma
Gary A. Ulaner et al.
RADIOLOGY (2015)
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma
Giuseppe Visani et al.
BLOOD (2014)
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Javier Briones et al.
HAEMATOLOGICA (2014)
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
Julie M. Vose et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ken Ohmachi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
Avichai Shimoni et al.
CANCER (2012)
Risk Factors and Outcome of Pulmonary Complications After Autologous Hematopoietic Stem Cell Transplant
Bekele Afessa et al.
CHEST (2012)
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
Giuseppe Visani et al.
BLOOD (2011)
90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z-BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study
Didier Decaudin et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Importance of Expert Central Review in the Diagnosis of Lymphoid Malignancies in a Regional Cancer Network
Ian E. Proctor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study
M. Musso et al.
BONE MARROW TRANSPLANTATION (2010)
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Response Assessment Before High-Dose Chemotherapy for Lymphoma: A Systematic Review and Meta-Analysis
Teruhiko Terasawa et al.
ONCOLOGIST (2010)
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma
B. S. Hoppe et al.
BONE MARROW TRANSPLANTATION (2009)
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jane N. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pretransplantation Positron Emission Tomography Scan Is the Main Predictor of Autologous Stem Cell Transplantation Outcome in Aggressive B-Cell Non-Hodgkin Lymphoma
Enrico Derenzini et al.
CANCER (2008)
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents
Lorenzo M. Leoni et al.
CLINICAL CANCER RESEARCH (2008)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
Amrita Krishnan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity
Jae-Cheol Jo et al.
ANNALS OF HEMATOLOGY (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
Bart W. Schot et al.
BLOOD (2007)
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
S Bhatia et al.
BLOOD (2005)
分享论文
